A carregar...
Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients
Background. New nontoxic targeted approaches are needed for patients with castrate resistant prostate cancer (CRPC). Our preclinical studies show that activated T cells (ATC) armed with anti-CD3 x anti-Her2 bispecific antibody (Her2Bi) kill prostate cancer cells lines, induce a Th(1) cytokine patter...
Na minha lista:
| Publicado no: | Prostate Cancer |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Hindawi Publishing Corporation
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4352947/ https://ncbi.nlm.nih.gov/pubmed/25802762 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2015/285193 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|